Soft tissue sarcoma
MONDO:0018078A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.
Also known as: malignant soft tissue tumor, malignant soft tissue tumour, connective tissue sarcoma, malignant mesenchymal tumor, malignant mesenchymal tumour, non-Rhabdo. soft tissue sarcoma, sarcoma of soft tissue, sarcoma of the soft tissue
3364 clinical trials for this condition and its sub-types, 296 tagged with Soft tissue sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Soft tissue sarcoma
-
Rhabdomyosarcoma 99 trials · 113 incl. sub-types
20 sub-types
- Alveolar rhabdomyosarcoma 9 trials
- Pleomorphic rhabdomyosarcoma 7 trials Sub-types →
- Embryonal rhabdomyosarcoma 4 trials Sub-types →
- Spindle cell rhabdomyosarcoma 3 trials Sub-types →
- Testis rhabdomyosarcoma 1 trial
- Breast rhabdomyosarcoma 0 trials
- Central nervous system rhabdomyosarcoma 0 trials
- Gallbladder rhabdomyosarcoma 0 trials
- Liver rhabdomyosarcoma 0 trials Sub-types →
- Mediastinum rhabdomyosarcoma 0 trials
- Oral rhabdomyosarcoma 0 trials
- Orbit rhabdomyosarcoma 0 trials Sub-types →
- Ovary rhabdomyosarcoma 0 trials
- Prostate rhabdomyosarcoma 0 trials Sub-types →
- Rectum rhabdomyosarcoma 0 trials Sub-types →
- Rhabdomyosarcoma of the cervix uteri 0 trials
- Rhabdomyosarcoma with mixed embryonal and alveolar features 0 trials
- Rhabdomyosarcoma, embryonal, 2 0 trials
- Uterine corpus rhabdomyosarcoma 0 trials
- Vaginal rhabdomyosarcoma 0 trials Sub-types →
-
Liposarcoma 58 trials · 83 incl. sub-types
19 sub-types
- Dedifferentiated liposarcoma 37 trials
- Myxoid/round cell liposarcoma 13 trials · 18 incl. sub-types Sub-types →
- Pleomorphic liposarcoma 8 trials
- Well-differentiated liposarcoma 5 trials Sub-types →
- Adult liposarcoma 0 trials
- Breast liposarcoma 0 trials
- Cutaneous liposarcoma 0 trials
- Esophagus liposarcoma 0 trials
- Fibroblastic liposarcoma 0 trials
- Gastric liposarcoma 0 trials
- Intracranial liposarcoma 0 trials
- Kidney liposarcoma 0 trials
- Larynx liposarcoma 0 trials
- Liposarcoma of bone 0 trials
- Liposarcoma of the ovary 0 trials Sub-types →
- Mediastinum liposarcoma 0 trials
- Mixed liposarcoma 0 trials
- Pediatric liposarcoma 0 trials
- Vulvar liposarcoma 0 trials
-
Angiosarcoma 37 trials · 82 incl. sub-types
19 sub-types
- Kaposi's sarcoma 45 trials Sub-types →
- Skin angiosarcoma 6 trials
- Breast angiosarcoma 1 trial
- Angiosarcoma of the scalp 0 trials
- Aorta angiosarcoma 0 trials
- Bone angiosarcoma 0 trials
- Central nervous system angiosarcoma 0 trials
- Conventional angiosarcoma 0 trials
- Gallbladder angiosarcoma 0 trials
- Liver angiosarcoma 0 trials
- Mediastinum angiosarcoma 0 trials
- Ovarian angiosarcoma 0 trials
- Pediatric angiosarcoma 0 trials
- Prostate angiosarcoma 0 trials
- Pulmonary artery leiomyosarcoma 0 trials
- Pulmonary vein leiomyosarcoma 0 trials
- Spleen angiosarcoma 0 trials
- Superior vena cava angiosarcoma 0 trials Sub-types →
- Thyroid gland angiosarcoma 0 trials
-
Rhabdoid tumor 63 trials · 75 incl. sub-types
5 sub-types
- Atypical teratoid rhabdoid tumor 35 trials · 36 incl. sub-types Sub-types →
- Rhabdoid tumor of the kidney 7 trials
- Extrarenal rhabdoid tumor 1 trial
- Familial rhabdoid tumor 0 trials · 1 incl. sub-types Sub-types →
- Striated muscle rhabdoid tumor 0 trials
-
Central nervous system sarcoma 2 trials · 74 incl. sub-types
12 sub-types
- Malignant peripheral nerve sheath tumor 36 trials · 38 incl. sub-types Sub-types →
- Atypical teratoid rhabdoid tumor 35 trials · 36 incl. sub-types Sub-types →
- Brain sarcoma 0 trials Sub-types →
- Central nervous system angiosarcoma 0 trials
- Central nervous system extraskeletal osteosarcoma 0 trials
- Central nervous system fibrosarcoma 0 trials
- Central nervous system leiomyosarcoma 0 trials Sub-types →
- Central nervous system rhabdomyosarcoma 0 trials
- Intracranial extraskeletal myxoid chondrosarcoma 0 trials
- Isolated melanotic schwannoma 0 trials
- Meningeal sarcoma 0 trials Sub-types →
- Spinal cord sarcoma 0 trials
-
Leiomyosarcoma 62 trials · 72 incl. sub-types
31 sub-types
- Leiomyosarcoma of the corpus uteri 9 trials Sub-types →
- Ovary leiomyosarcoma 2 trials
- Retroperitoneal leiomyosarcoma 2 trials
- Inflammatory leiomyosarcoma 1 trial
- Small intestine leiomyosarcoma 1 trial
- Bone leiomyosarcoma 0 trials
- Breast leiomyosarcoma 0 trials
- Central nervous system leiomyosarcoma 0 trials Sub-types →
- Colon leiomyosarcoma 0 trials
- Conventional leiomyosarcoma 0 trials
- Cutaneous leiomyosarcoma 0 trials
- Epithelioid leiomyosarcoma 0 trials Sub-types →
- Esophagus leiomyosarcoma 0 trials
- Fallopian tube leiomyosarcoma 0 trials
- Gallbladder leiomyosarcoma 0 trials
- Gastric leiomyosarcoma 0 trials
- Heart leiomyosarcoma 0 trials
- Kidney leiomyosarcoma 0 trials
- Laryngeal leiomyosarcoma 0 trials
- Leiomyosarcoma of the cervix uteri 0 trials
- Liver leiomyosarcoma 0 trials Sub-types →
- Lung leiomyosarcoma 0 trials
- Mediastinum leiomyosarcoma 0 trials
- Myxoid leiomyosarcoma 0 trials Sub-types →
- Prostate leiomyosarcoma 0 trials
- Pulmonary artery leiomyosarcoma 0 trials
- Pulmonary vein leiomyosarcoma 0 trials
- Rectum leiomyosarcoma 0 trials Sub-types →
- Superior vena cava leiomyosarcoma 0 trials
- Vagina leiomyosarcoma 0 trials
- Vulvar leiomyosarcoma 0 trials
-
Synovial sarcoma 53 trials
5 sub-types
- Biphasic synovial sarcoma 0 trials
- Breast synovial sarcoma 0 trials
- Fibrous synovial sarcoma 0 trials
- Mediastinum synovial sarcoma 0 trials
- Monophasic synovial sarcoma 0 trials Sub-types →
-
Undifferentiated pleomorphic sarcoma 48 trials
3 sub-types
-
Desmoplastic small round cell tumor 26 trials
-
Myxofibrosarcoma 21 trials
-
Fibrosarcoma 9 trials · 21 incl. sub-types
11 sub-types
- Dermatofibrosarcoma protuberans 11 trials Sub-types →
- Low grade fibromyxoid sarcoma 4 trials Sub-types →
- Conventional fibrosarcoma 0 trials · 2 incl. sub-types Sub-types →
- Pediatric fibrosarcoma 0 trials · 2 incl. sub-types Sub-types →
- Bone fibrosarcoma 0 trials
- Breast fibrosarcoma 0 trials
- Central nervous system fibrosarcoma 0 trials
- Heart fibrosarcoma 0 trials
- Kidney fibrosarcoma 0 trials
- Liver fibrosarcoma 0 trials
- Small intestinal fibrosarcoma 0 trials
-
Alveolar soft part sarcoma 20 trials
2 sub-types
- Cervical alveolar soft part sarcoma 0 trials
- Vulvar alveolar soft part sarcoma 0 trials
-
Epithelioid sarcoma 20 trials
4 sub-types
- Adult epithelioid sarcoma 0 trials
- Childhood epithelioid sarcoma 0 trials
- Peripheral epithelioid sarcoma 0 trials
- Proximal-type epithelioid sarcoma 0 trials Sub-types →
-
Retroperitoneal sarcoma 17 trials
1 sub-type
- Retroperitoneal leiomyosarcoma 2 trials
-
Clear cell sarcoma 14 trials · 16 incl. sub-types
1 sub-type
- Clear cell sarcoma of kidney 2 trials
-
Liver sarcoma 1 trial · 10 incl. sub-types
7 sub-types
- Undifferentiated (embryonal) sarcoma 9 trials
- Bile duct sarcoma 0 trials Sub-types →
- Liver angiosarcoma 0 trials
- Liver extraskeletal osteosarcoma 0 trials
- Liver fibrosarcoma 0 trials
- Liver leiomyosarcoma 0 trials Sub-types →
- Liver rhabdomyosarcoma 0 trials Sub-types →
-
Skin sarcoma 1 trial · 9 incl. sub-types
5 sub-types
- Skin angiosarcoma 6 trials
- Cutaneous undifferentiated pleomorphic sarcoma 2 trials
- Cutaneous leiomyosarcoma 0 trials
- Cutaneous liposarcoma 0 trials
- Skin lymphangiosarcoma 0 trials
-
SMARCA4-deficient sarcoma of thorax 8 trials
-
Kidney sarcoma 0 trials · 8 incl. sub-types
7 sub-types
- Rhabdoid tumor of the kidney 7 trials
- Clear cell sarcoma of kidney 2 trials
- Anaplastic sarcoma of the kidney 0 trials
- Kidney fibrosarcoma 0 trials
- Kidney leiomyosarcoma 0 trials
- Kidney liposarcoma 0 trials
- Kidney osteogenic sarcoma 0 trials
-
Extraskeletal myxoid chondrosarcoma 7 trials
1 sub-type
-
Intimal sarcoma 4 trials
-
Extraskeletal Ewing sarcoma 3 trials
-
Undifferentiated round cell sarcoma 3 trials
-
Breast sarcoma 2 trials · 3 incl. sub-types
7 sub-types
- Breast angiosarcoma 1 trial
- Breast extraskeletal osteosarcoma 0 trials
- Breast fibrosarcoma 0 trials
- Breast leiomyosarcoma 0 trials
- Breast liposarcoma 0 trials
- Breast rhabdomyosarcoma 0 trials
- Breast synovial sarcoma 0 trials
-
Extraosseous osteosarcoma 2 trials
7 sub-types
- Adult extraskeletal osteosarcoma 0 trials
- Breast extraskeletal osteosarcoma 0 trials
- Central nervous system extraskeletal osteosarcoma 0 trials
- Childhood extraosseous osteosarcoma 0 trials
- Kidney osteogenic sarcoma 0 trials
- Liver extraskeletal osteosarcoma 0 trials
- Mediastinal extraskeletal osteosarcoma 0 trials
-
Ovarian sarcoma 0 trials · 2 incl. sub-types
4 sub-types
- Ovary leiomyosarcoma 2 trials
- Liposarcoma of the ovary 0 trials Sub-types →
- Ovarian angiosarcoma 0 trials
- Ovary rhabdomyosarcoma 0 trials
-
Heart sarcoma 1 trial
3 sub-types
- Heart fibrosarcoma 0 trials
- Heart leiomyosarcoma 0 trials
- Malignant cardiac peripheral nerve sheath neoplasm 0 trials
-
Small intestinal sarcoma 0 trials · 1 incl. sub-types
2 sub-types
- Small intestine leiomyosarcoma 1 trial
- Small intestinal fibrosarcoma 0 trials
-
Testis sarcoma 0 trials · 1 incl. sub-types
1 sub-type
- Testis rhabdomyosarcoma 1 trial
-
Anus sarcoma 0 trials
2 sub-types
- Anus leiomyosarcoma 0 trials
- Anus rhabdomyosarcoma 0 trials
-
Bladder sarcoma 0 trials
-
Esophagus sarcoma 0 trials
2 sub-types
- Esophagus leiomyosarcoma 0 trials
- Esophagus liposarcoma 0 trials
-
Gallbladder sarcoma 0 trials
3 sub-types
- Gallbladder angiosarcoma 0 trials
- Gallbladder leiomyosarcoma 0 trials
- Gallbladder rhabdomyosarcoma 0 trials
-
Laryngeal sarcoma 0 trials
2 sub-types
- Laryngeal leiomyosarcoma 0 trials
- Larynx liposarcoma 0 trials
-
Lung sarcoma 0 trials
1 sub-type
- Lung leiomyosarcoma 0 trials
-
Mediastinum sarcoma 0 trials
7 sub-types
- Malignant melanocytic peripheral nerve sheath tumor of mediastinum 0 trials
- Mediastinal extraskeletal osteosarcoma 0 trials
- Mediastinum angiosarcoma 0 trials
- Mediastinum leiomyosarcoma 0 trials
- Mediastinum liposarcoma 0 trials
- Mediastinum rhabdomyosarcoma 0 trials
- Mediastinum synovial sarcoma 0 trials
-
Myxosarcoma 0 trials
-
Pancreas sarcoma 0 trials
-
Paranasal sinus sarcoma 0 trials
-
Penile sarcoma 0 trials
-
Prostate sarcoma 0 trials
4 sub-types
- Prostate angiosarcoma 0 trials
- Prostate leiomyosarcoma 0 trials
- Prostate rhabdomyosarcoma 0 trials Sub-types →
- Prostate stromal sarcoma 0 trials
-
Stromal sarcoma 0 trials
1 sub-type
- Prostate stromal sarcoma 0 trials
-
Thyroid sarcoma 0 trials
1 sub-type
- Thyroid gland angiosarcoma 0 trials
-
Trachea sarcoma 0 trials
-
Vagina sarcoma 0 trials
3 sub-types
- Endometrioid stromal sarcoma of the vagina 0 trials
- Vagina leiomyosarcoma 0 trials
- Vaginal rhabdomyosarcoma 0 trials Sub-types →
-
Vulva sarcoma 0 trials
5 sub-types
- Vulvar alveolar soft part sarcoma 0 trials
- Vulvar childhood botryoid-type embryonal rhabdomyosarcoma 0 trials
- Vulvar leiomyosarcoma 0 trials
- Vulvar liposarcoma 0 trials
- Vulvar proximal-type epithelioid sarcoma 0 trials
Most studied deeper sub-types
-
Can a dual immune antibody plus radiation shrink metastatic sarcoma?
Disease control CompletedResearchers are testing a combination of the experimental antibody MEDI5752 and stereotactic body radiotherapy in people with metastatic soft tissue sarcoma that has spread to the lungs. MEDI5752 targets two immune checkpoints, PD-1 and CTLA-4, and the radiation is aimed at one l…
Phase 1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a Marine-Derived drug slow advanced soft tissue sarcoma?
Disease control CompletedThis phase III trial compares the chemotherapy drug trabectedin (Yondelis) with best supportive care in people with advanced soft tissue sarcoma, a rare cancer of the connective tissues. The goal is to see if trabectedin can delay tumor growth and improve outcomes compared to sup…
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a One-Two punch of immunotherapy and radiation tame sarcoma before surgery?
Disease control CompletedThis pilot trial is investigating whether giving two immunotherapy drugs, nivolumab and ipilimumab, along with radiation therapy before surgery can safely help treat soft tissue sarcoma. The study enrolls adults with resectable, intermediate-to-high grade sarcomas larger than 5 c…
Early phase 1 • Sponsor: University of Rochester • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Vitamin c boosts radiation for sarcoma? early trial shows promise
Disease control CompletedThis study tested whether giving high-dose vitamin C (ascorbate) alongside radiation therapy before surgery is safe and effective for people with advanced soft tissue sarcoma. 25 participants received vitamin C infusions three times a week during radiation. The goal was to see if…
Phase 1/2 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill may keep soft tissue sarcoma in check after chemo
Disease control CompletedThis study tested whether taking anlotinib pills after initial chemotherapy can help keep advanced soft tissue sarcoma from growing. 49 adults with certain types of sarcoma took anlotinib daily. The goal was to see how long the cancer stayed stable and to check safety. Anlotinib …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Drug combo aims to shrink Hard-to-Treat sarcomas
Disease control CompletedThis phase 2 trial tests a combination of two drugs—chidamide and toripalimab—in people with advanced soft-tissue sarcoma that has not responded to standard treatments. Chidamide is a pill that may help the immune system recognize cancer cells, while toripalimab is an immunothera…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy boosts chemo against rare sarcomas?
Disease control CompletedThis study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and w…
Phase 2 • Sponsor: Alexander Z. Wei, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental t cell therapy targets sarcoma in small early trial
Disease control CompletedThis early-phase trial tested a personalized cell therapy for people with advanced bone or soft tissue sarcoma that had stopped responding to standard treatment. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells carrying a speci…
Phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo shows promise for rare sarcoma
Disease control CompletedThis phase 2 trial tested a combination of two drugs—anlotinib (a targeted therapy) and toripalimab (an immunotherapy)—in 70 people with advanced soft-tissue sarcoma that had stopped responding to standard treatment. The goal was to see if the combo could shrink tumors or slow di…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental combo shows promise in tough sarcoma
Disease control CompletedThis early-phase trial tested a combination of two drugs—LVGN6051, an experimental immune therapy, and anlotinib, a targeted cancer pill—in 39 adults with advanced soft tissue sarcoma that had stopped responding to standard treatments. The main goals were to check safety and find…
Phase 1/2 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New Drug-Coated membrane targets sarcoma after surgery
Disease control CompletedThis early-stage trial tested a special membrane loaded with the drug SN-38 in 21 people with recurrent or advanced retroperitoneal sarcoma. The membrane was placed in the surgical area after tumor removal to see if it is safe and tolerable. The goal is to find the right dose and…
Phase 1 • Sponsor: CEBIOTEX • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for rare sarcoma? drug combo tested in 44 patients
Disease control CompletedThis study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (doxorubicin) could help people with advanced soft tissue sarcoma that has spread or come back. The trial included 44 adults whose cancer could be measured and who were healthy enough for …
Phase 1/2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control CompletedThis study tested a combination of two drugs, cobimetinib and atezolizumab, in children and adults with advanced soft tissue sarcoma that has spread. The goal was to see if the combo is safe and can stop tumors from growing. About 229 people took part, and researchers measured ho…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy duo takes on rare sarcoma in new trial
Disease control CompletedThis phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and relatlimab, can help people with advanced or metastatic soft-tissue sarcoma. The study enrolled 68 adults whose tumors had a specific immune structure. Researchers measured how many patients had th…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising drug cocktail targets tough sarcomas in young patients
Disease control CompletedThis study tested a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, in 59 teenagers and young adults whose sarcoma (a type of bone or soft tissue cancer) had returned or not responded to standard treatment. The main goals were to see if the drug combo could…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Cancer drug shows promise in keeping sarcoma in check
Disease control CompletedThis phase 2 trial tested whether the drug regorafenib (Stivarga) could help keep metastatic soft tissue sarcoma from growing after initial chemotherapy. 127 adults whose cancer was stable or shrinking after six cycles of doxorubicin-based chemo were randomly assigned to receive …
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Drug holiday or not? sarcoma study tests best strategy
Disease control CompletedThis study looked at 53 adults with advanced soft tissue sarcoma who had stable disease or improvement after 6 cycles of trabectedin. Half continued the drug, while the other half took a break (drug holiday). The goal was to see which approach better delays cancer progression and…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for sarcoma patients: drug slows tumor growth in late-stage trial
Disease control CompletedThis study tested the drug regorafenib in 219 adults with soft tissue sarcoma that had spread and was no longer responding to standard chemotherapy. Participants were randomly assigned to receive either regorafenib or a placebo. The main goal was to see if the drug could delay ca…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy for rare sarcoma shows promise in early trial
Disease control CompletedThis early-phase trial tested whether adding a drug called avelumab to radiation therapy is safe for people with advanced soft-tissue sarcoma that has spread. Twelve adults with at least two tumors not curable by standard treatments took part. The main goal was to check for side …
Phase 1/2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a cancer drug boost radiation for rare sarcomas?
Disease control CompletedThis early-phase trial tested whether adding the drug olaparib to standard radiation therapy is safe for people with advanced soft-tissue sarcoma that cannot be removed by surgery. 41 participants received olaparib pills alongside daily radiation for about 7.5 weeks. The main goa…
Phase 1 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immune cells take on sarcoma in early trial
Disease control CompletedThis early-phase trial tested a treatment that uses a patient's own immune cells (called TILs) to fight soft tissue sarcoma. Nine young adults received chemotherapy to prepare their bodies, then an infusion of their own TILs plus high-dose IL-2 to boost the immune response. The m…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo shows promise for Hard-to-Treat sarcomas
Disease control CompletedThis study tested a combination of two chemotherapy drugs—trabectedin and cyclophosphamide—in 50 adults with advanced soft-tissue sarcomas that had already been treated. The goal was to find a safe dose and see if the combo could stop or slow tumor growth. Results showed the trea…
Phase 1/2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Heat and immune boost: new combo tackles Hard-to-Treat cancers
Disease control CompletedThis trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…
Phase 1/2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo therapy aims to shrink sarcomas before surgery
Disease control CompletedThis study tested whether giving a targeted drug called Apatinib along with radiation therapy before surgery is safe and effective for people with soft tissue sarcoma in the arms, legs, or trunk. 30 adults took part. The main goal was to see how many had major wound problems with…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a pill make radiation work better for sarcoma patients?
Disease control CompletedThis phase 2 trial tested whether adding the drug fluzoparib to standard preoperative radiation therapy improves outcomes for people with soft tissue sarcoma in the arms, legs, or trunk. Fifty-two adults took part, receiving either radiation alone or radiation plus fluzoparib bef…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo shows promise for rare cancers
Disease control CompletedThis study tested a combination of two drugs—pembrolizumab (an immunotherapy) and cyclophosphamide (a chemotherapy)—in 129 people with advanced sarcomas that had spread or could not be removed by surgery. The goal was to see if the combination could shrink tumors or stop them fro…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo shows promise in Hard-to-Treat sarcomas
Disease control CompletedThis study tested a drug called ADI-PEG 20 combined with two chemotherapy drugs (gemcitabine and docetaxel) in 98 people with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer. The goal was to see if the combination could slow cancer growth better than…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental combo therapy targets hard-to-treat sarcoma
Disease control CompletedThis study tested a two-step treatment for people with advanced soft tissue sarcoma that had stopped responding to standard therapy. First, a drug called LTX-315 was injected into a tumor to attract immune cells. Then, that tumor was removed, and the immune cells were grown in a …
Phase 2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and eribulin, in 30 people with advanced soft tissue sarcomas (liposarcoma or leiomyosarcoma) that could not be removed by surgery or had spread. The goal was to see if the combo could shrink tumors or slow their growth. Th…
Phase 1/2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Fewer radiation sessions before sarcoma surgery shows promise in early trial
Disease control CompletedThis pilot study tested a shorter course of radiation (hypofractionated) given before surgery for soft tissue sarcoma of the arm, leg, or chest wall. The goal was to see if this approach is safe, feasible, and controls the tumor locally. Thirty-five adults with localized sarcoma …
Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Personalized chemo shows promise against rare sarcomas
Disease control CompletedThis Phase 3 trial tested whether giving chemotherapy based on the specific type of soft tissue sarcoma works better than a one-size-fits-all approach. 550 adults with high-risk sarcomas in the arms or trunk were randomly assigned to standard chemo or a chemo regimen matched to t…
Phase 3 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental combo shrinks sarcomas before surgery?
Disease control CompletedThis early-phase trial tested a drug called navtemadlin given alongside radiation therapy before surgery for soft tissue sarcoma. The goal was to find a safe dose and see if the combination could shrink tumors, making surgery easier. 39 patients with intermediate or high-grade sa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested the combination of two drugs—trabectedin and durvalumab—in 40 people with advanced soft-tissue sarcoma or ovarian cancer that had not responded to prior treatments. The main goal was to find a safe dose and check for side effects. Researchers also lo…
Phase 1 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 26, 2026 14:10 UTC
-
New cancer drug EVT801 tested in humans for first time
Disease control CompletedThis early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 cap…
Phase 1 • Sponsor: Kazia Therapeutics Limited • Aim: Disease control
Last updated Jun 26, 2026 13:12 UTC
-
AI reads MRI scans to spot hidden sarcomas
Diagnosis CompletedThis study tested whether artificial intelligence (AI) can help doctors tell the difference between cancerous and non-cancerous soft tissue lumps using MRI scans. 186 patients with soft tissue masses had extra MRI images taken. The AI was trained to identify which lumps were sarc…
Sponsor: The Leeds Teaching Hospitals NHS Trust • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Smart patch could spot chemo side effects before they become dangerous
Symptom relief CompletedThis trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watc…
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Ancient Mind-Body practice tested as fatigue fighter for men after cancer
Symptom relief CompletedThis study investigates whether a 12-week program of tai chi and qigong (called Body Mind Training) can reduce fatigue in male cancer survivors aged 55 and older. Participants are randomly assigned to the mind-body training, a light exercise-only group, or a usual-care group. Res…
Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden cancer in kids
Knowledge-focused CompletedThis study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Gene test aims to personalize sarcoma treatment
Knowledge-focused CompletedThis study looked at whether advanced genetic testing (called NGS) can be done quickly enough to help guide treatment choices for people with advanced soft-tissue sarcoma. About 600 adults with this rare cancer took part. The goal was to see if using genetic information to pick t…
Phase 3 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Could a common Anti-Nausea pill change how chemo works?
Knowledge-focused CompletedThis study looked at 59 people with soft tissue sarcoma who were getting chemotherapy with doxorubicin and ifosfamide. Researchers wanted to see if adding the anti-nausea drug aprepitant changed the amount of ifosfamide in the blood. Patients had blood samples taken during their …
Phase 4 • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Can a simple test predict who will respond to this sarcoma drug?
Knowledge-focused CompletedThis study aims to find biological markers that can predict whether the drug trabectedin will work in patients with certain types of soft-tissue sarcoma. Researchers will collect tumor biopsies and blood samples from 29 participants before and during treatment. The goal is to use…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Could a Radiation-Free MRI replace risky scans for kids with cancer?
Knowledge-focused CompletedThis study tested whether a special MRI technique called diffusion-weighted MRI (DWI-MRI) can safely and accurately stage sarcomas in children without using radiation. 98 children with bone or soft-tissue sarcomas received DWI-MRI scans, and researchers compared the results to st…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Massive tumor study counts rare gene fusions
Knowledge-focused CompletedThis completed study examined tumor samples from 3820 people with advanced solid tumors to find how many have NTRK gene fusions. Researchers used genetic testing to identify these rare changes. The study did not test any treatment, but aims to guide future targeted therapy decisi…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Can we map a Tumor's genes fast enough to help patients?
Knowledge-focused CompletedThis pilot study tested whether advanced genetic sequencing of tumors can be done quickly enough to guide treatment decisions. Researchers took blood and tumor samples from 24 adults with advanced soft-tissue sarcoma or metastatic colorectal cancer. They measured how long it took…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:40 UTC
-
Massive sarcoma study reveals Real-World treatment patterns
Knowledge-focused CompletedThis study looked back at medical records of over 2,100 patients with metastatic soft tissue sarcoma treated in France between 1990 and 2013. Researchers analyzed which treatments patients received, including chemotherapy and local therapies, and how long they lived. The goal is …
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:46 UTC